Eikon Therapeutics (EIKN) investor relations material

Executive summary

• Late-stage clinical biopharmaceutical company advancing a pipeline of oncology drug candidates targeting high unmet needs in large indications.

• Advanced clinical programs with seven abstracts accepted for ESMO 2026, covering all four clinical candidates and initial findings for two new agents.

• Presented encouraging data at ASCO 2026 for EIK1001 in NSCLC and EIK1003 in breast and ovarian cancers.

• Net loss of $171.4M for the six months ended June 30, 2026, with an accumulated deficit of $1.1B.

• Cash, cash equivalents, and marketable securities totaled $531.2M as of June 30, 2026.

Financial highlights

• Ended Q2 2026 with $531.2M in cash, cash equivalents, and marketable securities.

• Research and development expenses increased 16% year-over-year to $145.5M for the six months ended June 30, 2026.

• General and administrative expenses decreased 36% year-over-year to $35.2M, primarily due to prior-year impairments.

• Net loss attributable to common stockholders was $88.4M for Q2 2026, down from $105.2M in Q2 2025.

• Net cash used in operating activities was $154.8M for the six months ended June 30, 2026.

Outlook and guidance

• Cash runway expected to fund operations into the second half of 2027.

• Full combination data for EIK1001 in NSCLC and updated data for other candidates to be presented at ESMO 2026.

• IND submission for EIK1006 anticipated by year-end 2026.

• Additional capital will be needed beyond 2027 to maintain operations and advance development programs.